Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 8-K (Current Report)
Date of Report: April 28, 2025 (Events reported through May 5, 2025)
Reporting Period: This filing covers specific corporate events occurring between April 28, 2025, and May 5, 2025, rather than a standard financial quarter.
Key Financial Metrics and Capital Structure
Debt and Liquidity:
- New Debt: Borrowed $100,000 from The Tiger Cub Trust (controlled by CEO Jacob D. Cohen) on May 2, 2025.
- Interest Rate: 18% per annum, compounded monthly.
- Maturity: May 2, 2026, or earlier upon a Qualified Financing or default.
- Prepayment Terms: Mandatory prepayment within five business days of a Qualified Financing; voluntary prepayment requires a "Make Whole Amount" premium.
- Series B Conversions: Converted 400 shares of Series B Convertible Preferred Stock into 293,333 shares of common stock (100 shares on April 28; 300 shares on May 1).
- Conversion Price: $1.50 per share.
- Settlement Shares: Issued 62,500 restricted common shares to 1800 Diagonal Lending, LLC to settle litigation.
- Total Outstanding Shares: 11,034,023 shares of common stock following these issuances.
The filing text does not provide a clear value for revenue, profit, cash flow, or operating margins.
Material Changes and Events
- Related-Party Transaction: Entered into a material definitive agreement (Promissory Note) with a trust controlled by the CEO and Chairman.
- Capital Structure Change: Significant dilution occurred via the conversion of preferred stock and the issuance of settlement shares, increasing the total share count to over 11 million.
- Litigation Resolution: Dismissed a lawsuit with prejudice against the Company and CEO via a settlement agreement involving equity issuance rather than cash payment.
Outlook, Risks, and Contingencies
Management Commentary and Risks:
- Financing Trigger: The new debt instrument contains a mandatory prepayment clause triggered by any future "Qualified Financing," which could impact future capital raising strategies.
- Default Penalties: In the event of default or bankruptcy, the principal amount automatically increases by the "Make Whole Amount," significantly increasing the debt burden.
- Related-Party Risk: The lender for the new debt is controlled by the CEO, creating a related-party transaction risk.
- Legal Contingency: The settlement agreement resolves prior claims but resulted in equity dilution.
The filing text does not provide forward-looking financial guidance or revenue projections.
Investor Verification Checklist
- Verify the exact terms of the "Make Whole Amount" calculation in the full Promissory Note (Exhibit 10.1).
- Confirm the definition of "Qualified Financing" to understand triggers for mandatory debt repayment.
- Review the impact of the 293,333 converted shares and 62,500 settlement shares on existing shareholder dilution.
- Assess the Company's current cash position to determine the ability to service the 18% interest on the new $100,000 note.
- Check for any other pending litigation or related-party transactions not disclosed in this specific 8-K.